The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients.
"With today's action, children with this devastating, degenerative disease will have an FDA-approved treatment option and the potential to live longer," said Christine Nguyen, Deputy Director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA's Center for Drug Evaluation and Research. "The FDA will continue to work with the rare disease community to advance drug development for patients with Menkes disease and other rare conditions."
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com